Shares of Lexicon Pharmaceuticals Inc. (LXRX) soared more than 61% on Monday, following positive results from the company’s phase III trial of its oral drug candidate Telotristat etiprate in cancer patients with Carcinoid syndrome.
Forex – financial instrument.Forex news
Shares of Lexicon Pharmaceuticals Inc. (LXRX) soared more than 61% on Monday, following positive results from the company’s phase III trial of its oral drug candidate Telotristat etiprate in cancer patients with Carcinoid syndrome.